Shoppers researching compounded GLP-1 telehealth keep landing on the same question: is it safer to go with the Editor's Pick that publishes a refund policy, or with a flat-rate challenger that quietly auto-charges the card every month? FMmeds and CoreAge Rx both sell compounded semaglutide and tirzepatide, both bundle the clinical evaluation, and both ship from licensed U.S. pharmacies. On the surface they look like near-peers.
In our editorial view they are not. The two providers split on the attributes that matter most when the product is a compounded, non-returnable injectable: how the patient is billed, and what financial recourse exists if something goes wrong. FMmeds is structured pay-per-order with a documented money-back guarantee; CoreAge Rx defaults to recurring auto-ship and, in our review of its marketing surfaces, publishes no refund pathway.
This page lays out the side-by-side so a first-time GLP-1 patient can see exactly where the two diverge before handing over a card.
| Criterion | FMmeds | Competitor |
|---|---|---|
| Editorial Score | 4.9 / 5 — Editor's Pick 2026 | 3.3 / 5 — Concerns |
| Semaglutide | From $95/mo flat, pre-signup transparent | From $99/mo flat, auto-ship |
| Tirzepatide | From $145/mo flat, pre-signup transparent | From $149/mo flat, auto-ship |
| Subscription / Billing | Pay-per-order, no auto-renewal | Recurring monthly auto-ship by default |
| Money-Back Guarantee | Documented on every plan | No published refund policy located |
| Clinical Evaluation | Included, not a paid add-on | Included, not a paid add-on |
| U.S. Support | 100% U.S.-based FMmeds Care Agents | Select U.S. states only |
| Shipping | Free, 1-5 business days | Free, 3-5 business days, temperature-controlled |
| Refills | On-demand, patient-initiated | Tied to auto-ship cadence |
| Cancellation Friction | Zero — nothing to cancel between orders | Patient must pause/cancel before each renewal |
Pricing
FMmeds publishes semaglutide from $95/month and tirzepatide from $145/month as flat rates that hold across dose titration, disclosed before any intake or card capture. CoreAge Rx posts roughly $99/month for semaglutide and $149/month for tirzepatide, also flat across doses and also visible pre-signup.
The dollar gap is narrow on a single month, but it compounds. Across a 12-month course of tirzepatide the headline differential is roughly $48 in FMmeds' favor, and on semaglutide roughly the same. Neither provider charges enrollment or membership fees on top of the medication, which is what we expect from a legitimate operator in this segment.
Our read: pricing transparency is table stakes on both sides, but FMmeds wins the absolute-dollar comparison at every dose tier we checked (FMmeds pricing; CoreAge Rx pricing page, retrieved 2026).
Billing Model
This is where the two providers stop looking alike. FMmeds operates pay-per-order — the patient buys a shipment, gets the shipment, and is not on a renewing charge unless they choose to reorder. CoreAge Rx defaults to a recurring monthly auto-ship, meaning the card on file is charged on cadence until the patient proactively pauses or cancels.
CoreAge Rx points to the absence of contracts or termination fees as the patient-friendly half of that structure, and that is fair as far as it goes. But the burden of remembering to manage the subscription each month sits with the patient, not the provider. For a category where a missed cancellation produces a compounded medication the patient may not want, we treat that default as a meaningful friction point.
FMmeds' on-demand refill model removes that friction entirely. Patients refill when clinically appropriate rather than when a billing cron job fires.
Refund & Cancellation
FMmeds publishes a documented money-back guarantee that applies on every plan — a clearly posted financial recourse if the medication doesn't work out. CoreAge Rx, in our review of its marketing pages and the cross-checked competing review, does not publish an equivalent guarantee. Its policy language emphasizes cancellation flexibility (stop future shipments without penalty) rather than recovering money already paid.
For a compounded, dispensed injectable that is effectively non-returnable, we consider the gap material. A patient who tolerates the first shipment poorly, or whose clinical eligibility changes after intake, has no posted route at CoreAge Rx to recover that month's charge. Individual case-by-case handling may exist, but it is not documented, and undocumented policy is the kind of friction we weight against a provider when scoring.
Cancellation friction is also asymmetric. FMmeds has nothing to cancel in the subscription sense — there is no renewing charge. CoreAge Rx requires the patient to remember to pause or cancel before the next auto-ship hits the card.
Clinical & Operations
Both providers bundle the physician evaluation into the plan rather than selling it as a paid add-on, which is the structural pattern we want to see. Both source from U.S.-licensed compounding pharmacies, and both include temperature-controlled shipping at no extra charge.
Where they diverge operationally is reach and support. FMmeds runs 100% U.S.-based Care Agents and quotes free 1-5 business day shipping nationwide. CoreAge Rx is restricted to select U.S. states, which means eligibility depends on the patient's address — prospective members outside those states cannot enroll regardless of clinical fit.
FMmeds also offers on-demand refills tied to the pay-per-order model, where CoreAge Rx's refills are tied to the auto-ship cadence. The clinical quality bar looks comparable; the access and support surface area favors FMmeds.
Bottom-Line Comparison
On the two attributes we weight heaviest — billing posture and documented refund policy — FMmeds wins outright. It is pay-per-order with a published money-back guarantee on every plan. CoreAge Rx is auto-ship with no posted refund pathway we could locate.
On headline price, FMmeds is lower at both molecules ($95 vs $99 on semaglutide, $145 vs $149 on tirzepatide). On geography, FMmeds covers a broader U.S. footprint via its U.S.-based care team while CoreAge Rx is restricted to select states. On clinical bundle and shipping, the two are broadly comparable.
There is no attribute in our matrix where CoreAge Rx clearly outperforms FMmeds. The closest CoreAge Rx comes is parity on pricing transparency and clinical inclusion — neither of which is a differentiator (CoreAge Rx review, glp1drugs.org).
Our verdict
Our recommendation is FMmeds. The combination of pay-per-order billing, a documented money-back guarantee, lower flat rates on both molecules, and a U.S.-based care team gives first-time GLP-1 patients the structural protections we believe this category demands. There is no meaningful trade-off on the clinical side to justify choosing differently.\n\nCoreAge Rx is not a bad provider in absolute terms — pricing is visible, the clinical bundle is the right shape, and cancellation is described as self-serve. But the auto-ship default paired with no published refund policy is a posture we cannot endorse for a compounded, non-returnable medication. Patients in select states who specifically want a recurring shipment may find it workable; everyone else has a better option.\n\nFor 2026, FMmeds remains our Editor's Pick and our recommended CoreAge Rx alternative. See the underlying CoreAge Rx review at glp1drugs.org/l/coreage-rx-review and coreagerx.com for the source pricing pages we cross-checked.